Chiesi Presents New Birch Triterpene Research
The company showcased clinical data on treatment options for epidermolysis bullosa at the annual PeDRA conference.
Updated on Oct. 15, 2026 in Allergies
Live Poll
Do you believe pharmaceutical companies are doing enough to develop treatments for rare diseases?
Chiesi Global Rare Diseases presented three research posters at the 14th Annual Conference of the Pediatric Dermatology Research Alliance. The findings focused on the mechanism and clinical performance of birch triterpenes for managing epidermolysis bullosa.
Why it matters
These presentations aim to strengthen the evidence base for birch triterpenes as a therapeutic option for patients. Epidermolysis bullosa is a rare condition that currently affects approximately 500,000 people globally.
Researchers presented 3 posters featuring clinical experience and mechanism-of-action data for birch triterpenes. FILSUVEZ is intended for clinical application as a 1 mm layer on affected wound surfaces.
The players
Chiesi Global Rare Diseases
This pharmaceutical company is a division of the Chiesi Group and focuses on developing therapies for rare genetic conditions.
Pediatric Dermatology Research Alliance
This professional organization facilitates research and clinical studies aimed at improving the treatment of dermatological conditions in children.
The details
The research highlights the use of FILSUVEZ, which has received regulatory approvals in several regions since 2022. The product requires specific application protocols, including covering the 1 mm topical layer with a dressing to treat wounds associated with the disease.
Timeline
June 2022: European Commission approved FILSUVEZ.
September 2022: UK MHRA approved FILSUVEZ.
December 2023: FDA approved FILSUVEZ.
May 5, 2026: Australia registered FILSUVEZ on the national register.
October 15-17, 2026: 14th Annual PeDRA Conference held in Virginia.
The Big Picture
The clinical expansion of birch triterpene therapies follows the established regulatory precedents set by the FDA's orphan drug approval pathway. This approach supports the development of treatments for rare conditions that historically lacked targeted medical interventions.
Patients and caregivers should consult with medical professionals regarding the proper application of FILSUVEZ as a 1 mm layer under dressing. This research update helps clarify the clinical evidence supporting the use of the medication in wound management.
The takeaway
Ongoing clinical research continues to broaden the understanding of how birch triterpenes function in wound healing for rare diseases. Healthcare providers and patients can look to these developments as evidence-based updates for long-term care management.
Further reading
Learn more about the latest research and management techniques for Allergies.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe pharmaceutical companies are doing enough to develop treatments for rare diseases?
